Change of Name of Nominated Adviser and Broker
29 October 2012
Instem plc
("Instem", the "Company" or the "Group")
Change of Name of Nominated Adviser and Broker
Instem plc (the “Company”) announces that following the completion of the merger between Nplus1 Brewin LLP and Singer Capital Markets Limited, the name of the Company’s Nominated Adviser and Broker has changed to Nplus1 Singer Advisory LLP (“N+1 Singer”) with immediate effect.
For further information, please contact:
Instem plc | www.instem.com |
Phil Reason, CEO | +44 (0) 1785 825600 |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Richard Lindley | |
Nick Owen | |
James White | |
Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
Paul Cornelius | or instem@walbrookpr.com |
Sam Allen | |
Helen Cresswell | |
Paul Whittington |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.